ArticleJournal of thrombosis and thrombolysis2020
The Impact of platelet-fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease.
Article in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04650529 (G-NUH), which is not on this map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
G-NUH (Gyeongsang National University Hospital) Registry
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Retinal vascular parameters as AI-driven biomarkers for pulse wave velocity assessment: a telemedicine strategy for cardiovascular risk assessment.Annals of medicine · 2026Article
- Clinical predictors and prognostic implications of HFpEF following STEMI based on HFA-PEFF score: a multicenter cohort analysis.Cardiovascular diagnosis and therapy · 2026Article
- Association and Prognostic Implications of "No-Reflow Phenomenon" and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction.JACC. Asia · 2025Article
- Platelet Reactivity and Fibrin Clot-Strength as assessed by TEG in Patients with Atrial Fibrillation undergoing Percutaneous Coronary Intervention.Journal of cardiovascular translational research · 2025Article
- Association Between Thromboelastography and Coagulation for Disease Severity Evaluation in Patients With Lower Extremity Arteriosclerosis Obliterans.Journal of clinical laboratory analysis · 2025Article
- The Use of Clot Strength as a Predictor of Thrombosis in Peripheral Artery Disease.Annals of vascular surgery · 2024Observational
- Influence of an abnormal ankle-brachial index on ischemic and bleeding events in patients undergoing percutaneous coronary intervention.The Korean journal of internal medicine · 2023Article
- Residual Inflammatory Risk and its Association With Events in East Asian Patients After Coronary Intervention.JACC. Asia · 2022Article
- Prevalence of adverse events during ticagrelor versus clopidogrel treatment and its association with premature discontinuation of dual antiplatelet therapy in East Asian patients with acute coronary syndrome.Frontiers in cardiovascular medicine · 2022Article
- SARS-CoV-2 proteins regulate inflammatory, thrombotic and diabetic responses in human arterial fibroblasts.Clinical immunology (Orlando, Fla.) · 2021Article
- Viscoelastic properties of clot formation and their clinical impact in East Asian versus Caucasian patients with stable coronary artery disease: a COMPARE-RACE analysis.Journal of thrombosis and thrombolysis · 2021Article
- Another Unmet Need against Residual Risk of Atherosclerotic Cardiovascular Disease: Can "Thrombin Pathway" Be a New Target for Therapy?Korean circulation journal · 2020Article
- Association Between Thrombogenicity Indices and Coronary Microvascular Dysfunction in Patients With Acute Myocardial Infarction.JACC. Basic to translational scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 2 countries.
Funding
Abstract
Patients with peripheral artery disease (PAD) have shown the increased risk of cardiovascular (CV) morbidity and mortality. This study sought to evaluate the impact of clot strength on prevalence and major adverse CV events (MACE) of PAD in high-risk patients. We enrolled patients undergoing percutaneous coronary intervention (PCI) (n = 1667) with available platelet-fibrin clot strength [thrombin-induced maximal amplitude (MA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.